UY30288A1 - Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol - Google Patents
Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterolInfo
- Publication number
- UY30288A1 UY30288A1 UY30288A UY30288A UY30288A1 UY 30288 A1 UY30288 A1 UY 30288A1 UY 30288 A UY30288 A UY 30288A UY 30288 A UY30288 A UY 30288A UY 30288 A1 UY30288 A1 UY 30288A1
- Authority
- UY
- Uruguay
- Prior art keywords
- reduce
- ppar
- benzoazepin
- oxi
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D233/16—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
La invención se refiere a compuestos de Fórmula (I) útiles como agonistas de PPAR. también se describen composiciones farmacéuticas y métodos de tratamiento de una o más afecciones que incluyen, pero sin limitación, diabetes, nefropatía, neuropatía, retinopatía, síndrome poliquístico ovárico, hipertensión, isquemia, accidente cerebrovascular, trastorno de intestino irritable, inflamación, cataratas, enfermedades cardiovasculares, síndrome X metabólico, hiper-LDL-colesterolemia, dislipidemia (que incluye hipertrigliceridemia, hipercolesterolemia, hiperlipidemia mixta e hipo-HDL-colesterolemia), aterosclerosis, obesidad y otros trastornos relacionados on el metabolismo de lípidos y sus complicaciones de la homeostasis de la energía, por la utilización de los compuestos de la invención.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79300106P | 2006-04-18 | 2006-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY30288A1 true UY30288A1 (es) | 2007-08-31 |
Family
ID=38610435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY30288A UY30288A1 (es) | 2006-04-18 | 2007-04-16 | Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol |
Country Status (30)
Country | Link |
---|---|
US (2) | US7678786B2 (es) |
EP (1) | EP2010289B1 (es) |
JP (1) | JP5232771B2 (es) |
KR (1) | KR101472370B1 (es) |
CN (1) | CN101479008B (es) |
AR (1) | AR060489A1 (es) |
AT (1) | ATE535282T1 (es) |
AU (1) | AU2007237928B2 (es) |
BR (1) | BRPI0711695A2 (es) |
CA (1) | CA2649700C (es) |
CO (1) | CO6160296A2 (es) |
CR (1) | CR10447A (es) |
EA (1) | EA016583B1 (es) |
EC (1) | ECSP088841A (es) |
ES (1) | ES2375754T3 (es) |
GT (1) | GT200800226A (es) |
HK (1) | HK1124797A1 (es) |
HN (1) | HN2008001559A (es) |
IL (1) | IL194850A (es) |
JO (1) | JO3444B1 (es) |
MX (1) | MX2008013534A (es) |
MY (1) | MY144637A (es) |
NO (1) | NO344334B1 (es) |
NZ (1) | NZ571998A (es) |
PE (1) | PE20080188A1 (es) |
TW (1) | TWI404712B (es) |
UA (1) | UA96150C2 (es) |
UY (1) | UY30288A1 (es) |
WO (1) | WO2007121432A2 (es) |
ZA (1) | ZA200809790B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
NZ587202A (en) * | 2008-01-04 | 2013-03-28 | Schabar Res Associates Llc | Methods for measuring a patient response upon administration of a drug and compositions thereof |
WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
RU2490257C2 (ru) | 2008-05-30 | 2013-08-20 | Такеда Фармасьютикал Компани Лимитед | Гетероциклическое соединение |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011134468A1 (en) | 2010-04-28 | 2011-11-03 | Leo Pharma A/S | Biaryl phosphodiesterase inhibitors |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
BR112013000925A2 (pt) | 2010-07-15 | 2020-12-01 | Bayer Intellectual Property Gmbh | compostos heterocíclicos como pesticidas |
AU2011296737A1 (en) | 2010-08-31 | 2013-04-11 | Snu R&Db Foundation | Use of the fetal reprogramming of a PPAR delta agonist |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013124380A1 (en) | 2012-02-24 | 2013-08-29 | Nestec S.A. | Peltatin for the treatment of chronic inflammatory disorders |
WO2013124382A1 (en) | 2012-02-24 | 2013-08-29 | Nestec S.A. | Peltatin for use in the treatment of cardiovascular disorders |
EP2817006A1 (en) | 2012-02-24 | 2014-12-31 | Nestec S.A. | Peltatin for use in the treatment of metabolic disorders |
WO2014152809A2 (en) * | 2013-03-14 | 2014-09-25 | The University Of Toledo | Analogs of pparo and 20-oh-pge2, and methods of using the same |
WO2016057322A1 (en) * | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
WO2021097034A1 (en) * | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases |
AU2021310264A1 (en) | 2020-07-15 | 2023-02-09 | Schabar Research Associates Llc | Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn |
US11324727B2 (en) | 2020-07-15 | 2022-05-10 | Schabar Research Associates, Llc | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2460689C3 (de) | 1974-12-20 | 1980-06-26 | Klinge Pharma Gmbh & Co, 8000 Muenchen | 13-disubstituierte Propanol-(2)-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US4125732A (en) | 1977-05-06 | 1978-11-14 | American Cyanamid Company | 2-Aryloxy-2-(phenoxyalkoxy)phenyl acetic acid and esters |
DE3026924A1 (de) | 1980-07-16 | 1982-02-18 | Klinge Pharma GmbH & Co, 8000 München | 1,3-diphenoxypropan-2-ol-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
DE3028776A1 (de) | 1980-07-29 | 1982-02-25 | Klinge Pharma GmbH & Co, 8000 München | Neue 1,3-diphenoxypropan-2-on-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
EP0056172B1 (en) | 1981-01-09 | 1985-04-03 | FISONS plc | Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them |
JPS58177934A (ja) | 1982-04-13 | 1983-10-18 | Takeda Chem Ind Ltd | ベンゾキノン誘導体 |
DE3366107D1 (en) | 1982-09-30 | 1986-10-16 | Merck Frosst Canada Inc | Leukotriene antagonists, their production, and compositions containing them |
US4820867A (en) * | 1983-04-21 | 1989-04-11 | Merck Frosst Canada, Inc. | Phenoxypropoxy halophenylacetic acids as leukotriene antagonists |
US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
JPS61268651A (ja) | 1985-05-23 | 1986-11-28 | Takeda Chem Ind Ltd | フエニル酢酸誘導体およびその製造法 |
EP0204349A3 (de) * | 1985-06-01 | 1990-01-03 | Dr. Karl Thomae GmbH | Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
JPH0714910B2 (ja) | 1988-12-13 | 1995-02-22 | 塩野義製薬株式会社 | 安定な結晶性の塩およびそれを含有するトロンボキサン受容体拮抗剤 |
US5487008A (en) | 1990-04-20 | 1996-01-23 | The Regents Of The University Of Michigan | Method and system for detecting the misfire of a reciprocating internal combustion engine in frequency domain |
US5360909A (en) | 1992-03-23 | 1994-11-01 | Terumo Kabushiki Kaisha | Phenoxyacetic acid compounds and medical preparations containing them |
US5726165A (en) | 1994-07-29 | 1998-03-10 | Smithkline Beecham P.L.C. | Derivatives of 4-(2-aminoethyl)phenoxymethyl-phosphonic and -phosphinic acid and pharmaceutical and veterinary uses therefor |
ATE245622T1 (de) | 1996-02-02 | 2003-08-15 | Merck & Co Inc | Antidiabetische mittel |
ES2241036T3 (es) | 1996-02-02 | 2005-10-16 | MERCK & CO., INC. | Procedimiento de tratamiento de diabetes y estados patologicos asociados. |
JP3268242B2 (ja) | 1996-11-14 | 2002-03-25 | 三共株式会社 | 縮合複素環化合物を含有する医薬 |
JP4427825B2 (ja) | 1997-07-24 | 2010-03-10 | アステラス製薬株式会社 | コレステロール低下作用を有する医薬組成物 |
GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
GB0031107D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
BR0210190A (pt) | 2001-06-07 | 2004-04-06 | Lilly Co Eli | Moduladores de receptores ativados de proliferador de peroxissomo |
KR20040019087A (ko) | 2001-07-30 | 2004-03-04 | 노보 노르디스크 에이/에스 | 신규 비닐 카르복실산 유도체 및 항당뇨제 등으로서그들의 사용 |
AU2002323776B2 (en) | 2001-08-10 | 2008-07-31 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator-responsive receptor Delta |
DE60210784T2 (de) * | 2001-08-29 | 2006-11-02 | Warner-Lambert Co. Llc | Orale antidiabetische wirkstoffe |
DE60232739D1 (de) * | 2001-10-12 | 2009-08-06 | Nippon Chemiphar Co | Aktivator des peroxisomproliferator-aktivierten rezeptors delta |
ITRM20020014A1 (it) | 2002-01-15 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del |
JP4383177B2 (ja) | 2002-03-01 | 2009-12-16 | スミスクライン ビーチャム コーポレーション | hPPAR活性化剤 |
US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
GB0214149D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
BR0314335A (pt) * | 2002-09-05 | 2005-07-26 | Novo Nordisk As | Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade |
ATE472526T1 (de) | 2002-10-28 | 2010-07-15 | High Point Pharmaceuticals Llc | Neue verbindungen und deren verwendung als ppar- modulatoren |
ATE469882T1 (de) | 2002-10-28 | 2010-06-15 | High Point Pharmaceuticals Llc | Neue verbindungen, die sich f r die behandlung von durch ppar vermittelten krankheiten eignen |
JP2006516254A (ja) * | 2003-01-06 | 2006-06-29 | イーライ・リリー・アンド・カンパニー | Pparモジュレータとしての縮合ヘテロ環誘導体 |
AU2003300131A1 (en) * | 2003-01-06 | 2004-11-04 | Eli Lilly And Company | Indole derivatives as ppar modulators |
EP1594955B1 (en) | 2003-02-14 | 2012-04-11 | Biogen Idec MA Inc. | An expression cassette and vector for transient or stable expression of exogenous molecules |
PA8594401A1 (es) * | 2003-02-21 | 2004-09-16 | Pfizer | Acidos carboxilicos de heteroarilo condensado como agonista del ppar |
US7244763B2 (en) * | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
US6987118B2 (en) * | 2003-05-21 | 2006-01-17 | Pfizer Inc. | Tetrahydroisoquinoline derivatives as PPAR-alpha activators |
US20060257987A1 (en) * | 2003-08-20 | 2006-11-16 | Gonzalez Valcarcel Isabel Cris | Ppar modulators |
ES2555031T3 (es) | 2003-09-19 | 2015-12-28 | Janssen Pharmaceutica N.V. | Ácidos y análogos 4-((fenoxialquilo)tio)-fenoxiacéticos |
EA012241B1 (ru) | 2003-09-19 | 2009-08-28 | Янссен Фармацевтика, Н.В. | 4-((феноксиалкил)тио)феноксиуксусные кислоты и их аналоги |
BRPI0416106A (pt) * | 2003-10-31 | 2007-01-02 | Janssen Pharmaceutica Nv | ácidos 4 -((fenoxialquil)tio)-fenoxiacéticos e análogos |
US20050203151A1 (en) * | 2003-12-19 | 2005-09-15 | Kalypsys, Inc. | Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions |
ATE461932T1 (de) | 2004-04-21 | 2010-04-15 | Schering Corp | Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors |
JP2008500358A (ja) * | 2004-05-25 | 2008-01-10 | メタボレックス インコーポレーティッド | Pparのモジュレーターとしての、二環式の置換されたトリアゾール、およびこれらの調製方法 |
RU2384565C2 (ru) | 2004-07-01 | 2010-03-20 | Ф.Хоффманн-Ля Рош Аг | Фенильные производные, содержащие ацетиленовую группу |
BRPI0515168A (pt) * | 2004-09-11 | 2008-07-08 | Sanofi Aventis Deutschland | 7-azaindóis, processos para sua preparação e seu uso como fármacos |
PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
MY145712A (en) | 2004-09-15 | 2012-03-30 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
MY147518A (en) * | 2004-09-15 | 2012-12-31 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
JO3006B1 (ar) * | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
CN101360743A (zh) * | 2006-01-30 | 2009-02-04 | Irm责任有限公司 | 作为ppar调节剂的多环的1,2,3,4-四氢-异喹啉衍生物和包含它们的组合物 |
GB0618963D0 (en) | 2006-09-26 | 2006-11-08 | Ucl Business Plc | Formulations and composites with reactive fillers |
-
2007
- 2007-04-16 PE PE2007000463A patent/PE20080188A1/es active IP Right Grant
- 2007-04-16 UY UY30288A patent/UY30288A1/es active IP Right Grant
- 2007-04-17 ES ES07760766T patent/ES2375754T3/es active Active
- 2007-04-17 CA CA2649700A patent/CA2649700C/en not_active Expired - Fee Related
- 2007-04-17 UA UAA200813306A patent/UA96150C2/ru unknown
- 2007-04-17 CN CN2007800226398A patent/CN101479008B/zh not_active Expired - Fee Related
- 2007-04-17 JO JOP/2007/0139A patent/JO3444B1/ar active
- 2007-04-17 EP EP07760766A patent/EP2010289B1/en active Active
- 2007-04-17 MY MYPI20084161A patent/MY144637A/en unknown
- 2007-04-17 AT AT07760766T patent/ATE535282T1/de active
- 2007-04-17 US US11/736,221 patent/US7678786B2/en active Active
- 2007-04-17 NZ NZ571998A patent/NZ571998A/en not_active IP Right Cessation
- 2007-04-17 TW TW096113405A patent/TWI404712B/zh not_active IP Right Cessation
- 2007-04-17 MX MX2008013534A patent/MX2008013534A/es active IP Right Grant
- 2007-04-17 WO PCT/US2007/066772 patent/WO2007121432A2/en active Application Filing
- 2007-04-17 EA EA200870445A patent/EA016583B1/ru unknown
- 2007-04-17 JP JP2009506716A patent/JP5232771B2/ja not_active Expired - Fee Related
- 2007-04-17 AR ARP070101628A patent/AR060489A1/es active IP Right Grant
- 2007-04-17 BR BRPI0711695-0A patent/BRPI0711695A2/pt not_active IP Right Cessation
- 2007-04-17 AU AU2007237928A patent/AU2007237928B2/en not_active Ceased
-
2008
- 2008-10-17 HN HN2008001559A patent/HN2008001559A/es unknown
- 2008-10-21 GT GT200800226A patent/GT200800226A/es unknown
- 2008-10-22 EC EC2008008841A patent/ECSP088841A/es unknown
- 2008-10-22 IL IL194850A patent/IL194850A/en active IP Right Grant
- 2008-10-24 CO CO08113909A patent/CO6160296A2/es unknown
- 2008-11-14 KR KR1020087027903A patent/KR101472370B1/ko active IP Right Grant
- 2008-11-17 ZA ZA2008/09790A patent/ZA200809790B/en unknown
- 2008-11-18 NO NO20084847A patent/NO344334B1/no not_active IP Right Cessation
- 2008-11-18 CR CR10447A patent/CR10447A/es unknown
-
2009
- 2009-03-09 HK HK09102249.6A patent/HK1124797A1/xx not_active IP Right Cessation
-
2010
- 2010-01-19 US US12/689,335 patent/US8633184B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY30288A1 (es) | Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol | |
CL2007001971A1 (es) | Ester isopropilico del acido 4-[5-metoxi-6-(2-metil-6-[1,2,4]triazol-1-il-piridin-3-ilamino)-pirimidin-4-iloxi]-piperidin-1-carboxilico, agonista del receptor rup3, modulador del metabolismo de glucosa; composicion farmaceutica; y uso para tratar trastornos metabolicos, como diabetes, hiperlipidemia, hiperglicemia, obesidad | |
MX2015001500A (es) | Compuestos antidiabeticos triciclicos. | |
CL2008002997A1 (es) | Compuestos derivados de bifenilo, moduladores gpr40; proceso de preparacion de intermediarios; composicion farmaceutica que los comprende; y su uso para tratar diabetes tipo ii, obesidad, hiperlipoproteinemia, hperglucemia, intolerancia a la glucosa, enfermedad cardiovascular, ateroesclerosis, nefropatia, dermatopatia y cancer. | |
CL2011000051A1 (es) | Compuestos derivados de piperidinilo, agonistas del receptor acoplado a la proteina g; composicion farmaceutica que los comprende; y su uso para la regulacion de la saciedad, tratar la obesidad, diabetes, sindrome metabolico, intolerancia ala glucosa, hiperlipidemias o hipertension, entre otras enfermedades. | |
AU2015263620A8 (en) | Antidiabetic tricyclic compounds | |
MX2015010935A (es) | Compuestos biciclicos antidiabeticos. | |
CR11393A (es) | Agonistas novedosos de los receptores de glucocorticoides | |
CL2011002745A1 (es) | Compuestos derivados de acidos grasos poliinsaturados; metodo de preparacion; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de trastornos cardiovasculares, metabolicos e inflamatorios, tales como, artritis reumatoide, aterosclerosis, diabetes, dislipidemia, entre otras. | |
GT201700143A (es) | Derivado de biarilo como agonista de gpr120 | |
UY31863A (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
NZ606827A (en) | Agonists of gpr40 | |
CL2008003655A1 (es) | Anticuerpo que reconoce los restos 28-35 del peptido beta-amiloide, composicion farmaceutica que lo comprende, util para tratar una enfermedad relacionada con el peptido beta-amiloide. | |
BR112014026881A2 (pt) | compostos inovadores | |
CL2008000422A1 (es) | El compuesto acido 4-[4-(2-adamantilcarbamoil)-5-terbutilpirazol-1-il]-benzoico; composicion farmaceutica; su uso como inhibidor de 11bhsd1, util en el tratamiento de la diabetes tipo 2 y la obesidad. | |
NO20083909L (no) | Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere | |
CL2012000937A1 (es) | Compuestos heterociclicos espiro derivados de ciclohexano, inhibidores de hsl; procedimiento de preparacion; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento de diabetes, sindrome metabolico, dislipidemia, aterosclerosis u obesidad. | |
ECSP12011606A (es) | Agonistas de gpr119 | |
NZ750252A (en) | Sulfonamides as gpr40- and gpr120-agonists | |
CL2016002809A1 (es) | Compuestos derivados de pirrol, piridina o piperidina sustituidos con heterociclos, moduladores del receptor acoplado a la proteína g 40 (gpr40); composición farmacéutica que los comprende; y su uso para el tratamiento de enfermedades como diabetes, retinopatía, neuropatía, aterosclerosis, obesidad e hipertensión. | |
CL2009000116A1 (es) | Compuestos derivados de heterotriciclos sustituidos, antagonistas del receptor crf; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento de trastornos afectivos, depresion, ansiedad y sindrome del colon irritable. | |
CO6321281A2 (es) | Derivados de tetrazol como moduladores de receptores de glutamato metabotropicos (mglurs) | |
EA201270039A1 (ru) | Новые агонисты gpr 119 | |
BR112017001847A2 (pt) | processo para a preparação de um composto de fórmula (i), mistura, composição e composto de fórmula (ii) | |
PE20090624A1 (es) | Diaminopirimidinas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
110 | Patent granted |
Effective date: 20190423 |